Repurposing Lovastatin Cytotoxicity against the Tongue Carcinoma HSC3 Cell Line Using a Eucalyptus Oil-Based Nanoemulgel Carrier
Tongue cancer is one of the most common carcinomas of the head and neck region. The antitumor activities of statins, including lovastatin (LV), and the essential oil of eucalyptus (Eu oil), have been adequately reported. The aim of this study was to develop a nanoemulgel containing LV combined with Eu oil that could then be made into a nanoemulsion and assessed to determine its cytotoxicity against the cell line human chondrosarcoma-3 (HSC3) of carcinoma of the tongue. An I-optimal coordinate-exchange quadratic mixture design was adopted to optimize the investigated nanoemulsions. The droplet size and stability index of the developed formulations were measured to show characteristics of the nanoemulsions. The optimized LV loaded self-nanoemulsifying drug delivery system (LV-Eu-SNEDDS) was loaded into the gelling agent Carbopol 934 to develop the nanoemulgel and evaluated for its rheological properties. The cytotoxic efficiency of the optimized LV-Eu-SNEDDS loaded nanoemulgel was tested for cell viability, and the caspase-3 enzyme test was used against the HSC3 cell line of squamous carcinoma of the tongue. The optimized nanoemulsion had a droplet size of 85 nm and a stability index of 93%. The manufactured nanoemulgel loaded with the optimum LV-Eu-SNEDDS exhibited pseudoplastic flow with thixotropic behavior. The developed optimum LV-Eu-SNEDDS-loaded nanoemulgel had the best half-maximal inhibitory concentration (IC50) and caspase-3 enzyme values of the formulations developed for this study, and these features improved the ability of the nanoemulsion-loaded gel to deliver the drug to the investigated target cells. In addition, the in vitro cell viability studies revealed the synergistic effect between LV and Eu oil in the treatment of tongue cancer. These findings illustrated that the LV-Eu-SNEDDS-loaded gel formulation could be beneficial in the local treatment of tongue cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Gels (Basel, Switzerland) - 8(2022), 3 vom: 12. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rizg, Waleed Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Essential oils |
|---|
| Anmerkungen: |
Date Revised 29.03.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/gels8030176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338536094 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338536094 | ||
| 003 | DE-627 | ||
| 005 | 20231226000906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/gels8030176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338536094 | ||
| 035 | |a (NLM)35323289 | ||
| 035 | |a (PII)176 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rizg, Waleed Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing Lovastatin Cytotoxicity against the Tongue Carcinoma HSC3 Cell Line Using a Eucalyptus Oil-Based Nanoemulgel Carrier |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Tongue cancer is one of the most common carcinomas of the head and neck region. The antitumor activities of statins, including lovastatin (LV), and the essential oil of eucalyptus (Eu oil), have been adequately reported. The aim of this study was to develop a nanoemulgel containing LV combined with Eu oil that could then be made into a nanoemulsion and assessed to determine its cytotoxicity against the cell line human chondrosarcoma-3 (HSC3) of carcinoma of the tongue. An I-optimal coordinate-exchange quadratic mixture design was adopted to optimize the investigated nanoemulsions. The droplet size and stability index of the developed formulations were measured to show characteristics of the nanoemulsions. The optimized LV loaded self-nanoemulsifying drug delivery system (LV-Eu-SNEDDS) was loaded into the gelling agent Carbopol 934 to develop the nanoemulgel and evaluated for its rheological properties. The cytotoxic efficiency of the optimized LV-Eu-SNEDDS loaded nanoemulgel was tested for cell viability, and the caspase-3 enzyme test was used against the HSC3 cell line of squamous carcinoma of the tongue. The optimized nanoemulsion had a droplet size of 85 nm and a stability index of 93%. The manufactured nanoemulgel loaded with the optimum LV-Eu-SNEDDS exhibited pseudoplastic flow with thixotropic behavior. The developed optimum LV-Eu-SNEDDS-loaded nanoemulgel had the best half-maximal inhibitory concentration (IC50) and caspase-3 enzyme values of the formulations developed for this study, and these features improved the ability of the nanoemulsion-loaded gel to deliver the drug to the investigated target cells. In addition, the in vitro cell viability studies revealed the synergistic effect between LV and Eu oil in the treatment of tongue cancer. These findings illustrated that the LV-Eu-SNEDDS-loaded gel formulation could be beneficial in the local treatment of tongue cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a essential oils | |
| 650 | 4 | |a experimental design | |
| 650 | 4 | |a nanosized delivery systems | |
| 650 | 4 | |a statins | |
| 650 | 4 | |a tongue cancer | |
| 700 | 1 | |a Hosny, Khaled M |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoud, Samar S |e verfasserin |4 aut | |
| 700 | 1 | |a Kammoun, Ahmed K |e verfasserin |4 aut | |
| 700 | 1 | |a Alamoudi, Abdulmohsin J |e verfasserin |4 aut | |
| 700 | 1 | |a Tayeb, Hossam H |e verfasserin |4 aut | |
| 700 | 1 | |a Bukhary, Haitham A |e verfasserin |4 aut | |
| 700 | 1 | |a Badr, Moutaz Y |e verfasserin |4 aut | |
| 700 | 1 | |a Murshid, Samar S A |e verfasserin |4 aut | |
| 700 | 1 | |a Alfayez, Eman |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a Mushtaq, Rayan Y |e verfasserin |4 aut | |
| 700 | 1 | |a Abualsunun, Walaa A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gels (Basel, Switzerland) |d 2014 |g 8(2022), 3 vom: 12. März |w (DE-627)NLM273273515 |x 2310-2861 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:3 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/gels8030176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 3 |b 12 |c 03 | ||